Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.

This House Resolution advocates for the inclusion of antiphospholipid syndrome (APS) testing as a standard component of prenatal screening. APS is an autoimmune condition that significantly increases the risk of blood clots, leading to adverse pregnancy outcomes such as miscarriages and stillbirths. Currently, professional medical associations only recommend APS testing after specific pregnancy losses, not as a routine screening. The resolution emphasizes that APS is responsible for a substantial percentage of recurrent pregnancy losses and can be detected via a blood test and effectively treated with blood thinners. By making APS testing standard, the resolution aims to prevent pregnancy complications, save lives, and reduce emotional distress for families. It specifically calls upon professional medical associations and guideline-setting bodies to revise their recommendations to incorporate this testing into standard prenatal care.